RetroSense Therapeutics to Present at 7th Annual Biotech Showcase Conference

Biotech Showcase 2015

ANN ARBOR, Mich.--()--RetroSense Therapeutics,(www.retro-sense.com) a privately-held biopharmaceutical company, today announced that Chief Executive Officer Sean Ainsworth will provide an update on the Company’s progress at the Biotech Showcase 2015 conference at 4:30 p.m. PST on Tuesday, January 13, 2015 at the Parc 55 Wyndham Hotel in San Francisco, CA. Recently designated with Orphan Drug Status, Retro-Sense’s lead product, RST-001 is being developed as a first-in-class gene therapy application of optogenetics designed to restore vision to those affected by retinal degenerative conditions.

About Optogenetics

Optogenetics refers broadly to means of conferring light sensitivity to cells that were not previously, or natively light sensitive. By applying optogenetics to retinas in which rod and cone photoreceptors have degenerated, RetroSense is conferring new light sensitivity to the retina, with the expectation of improved or restored vision. RST-001 is expected to have application to all forms of Retinitis Pigmentosa, independent of causative gene or mutation.

About Retinitis Pigmentosa

Retinitis pigmentosa is a genetic condition which leads to the progressive degeneration of rod and cone photoreceptors (cells found in the retina of the eye that sense light). Loss of these cells results in severe vision loss and blindness.

About RetroSense Therapeutics

RetroSense Therapeutics is a privately-held biotechnology company developing life-enhancing gene therapies designed to restore vision in patients suffering from blindness due to retinitis pigmentosa (RP) and advanced dry age-related macular degeneration (advanced dry-AMD). There are currently no FDA approved drugs to improve or restore vision in patients with these retinal degenerative conditions. The Company's approach to using optogenetics in vision restoration is based on pioneering, proprietary research conducted at Wayne State University and Massachusetts General Hospital. RetroSense has worldwide exclusive rights to the relevant intellectual property from both institutions. RetroSense is led by a team of seasoned veterans with deep experience in taking products from the discovery stage through to the clinic. For more information about RetroSense, visit http://www.retro-sense.com/.

Contacts

RetroSense Therapeutics
Amy Caterina
Media Relations
734-926-9314
amy@retro-sense.com

Release Summary

RetroSense announces that Chief Executive Officer Sean Ainsworth will provide an update on the Company’s progress at the Biotech Showcase 2015 conference at 4:30 p.m. PST on Tuesday, January 13, 2015.

Contacts

RetroSense Therapeutics
Amy Caterina
Media Relations
734-926-9314
amy@retro-sense.com